Identification of the NDC80-derived ALNEQIARL peptide as a tumor-associated HLA ligand. (A) Experimental strategy. (B) Mean NDC80 expression levels in different cancer cell lines. Only cancer types with at least 5 data points were considered. Whiskers indicate minimum to maximum. (C) Mean NDC80 expression of healthy tissues and corresponding cancer cell lines. (D) Mean NDC80 expression of adjacent healthy tissues and corresponding primary cancer tissues. (E) ELISpot results from 3 healthy donors and 2 biological replicates per donor. Data were normalized to results from CD14⁺ cells alone. EW served as control peptide. Error bars in panels C, D, and E denote standard deviation. ***P < .001 (Mann-Whitney test), ****P < .0001 (Wilcoxon matched-pairs signed-rank test). ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; GO, Gene Ontology. EW, Ewing sarcoma-derived HLA-A0201-binding peptide; EW, QLQNPSYDK; PHA, phytohemagglutinin.